⌕
Nurix Therapeutics · NRIX · Nasdaq
Tenet 85 · Strong
Compare
$14.67−5.23%At closeTenet 85 · Strong
$14.67−0.81 (−5.23%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$14.99+0.32 (+2.18%)
After hours: Nov 16, 2026, 4:14 PM ET

Nurix Therapeutics (NRIX) Earnings Forecast

Analysts expect Nurix Therapeutics (NRIX) to earn $2.35 a share in FY26, the average of 4 estimates as of Nov 13, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$2.35
4 analysts
FY27 consensus EPS
$−2.14
4 analysts · low $−3.48, high $−0.64
EPS revisions, 30 days
+20.4%
$1.95 to $2.35
Disagreement, FY26
521.9%
high to low, $−6.17 to $6.11

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect Nurix Therapeutics to lose $1.16 a share in FY30; 1 analyst publishes an estimate for FY30.

Forward P/E · FY26E
6.6×
$15.48 (as of close, Nov 13, 2026) ÷ $2.35 consensus EPS
Coverage · FY26
4 · 4
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $2.35, up 185.7% in 91 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 91 days. One step per nightly change.

−41.6%+89.4%+220.3%FY26 +185.7%FY27 −6.9%Aug 15Nov 13
EPS30 days90 daysshown aboveSince Jul 6
FY264 analysts▲ +20.4%$1.95 to $2.35▲ +185.7%$−2.75 to $2.35▲ +194.0%$−2.50 to $2.35
FY274 analysts▼ −4.5%$−2.05 to $−2.14▼ −6.9%$−2.00 to $−2.14▲ +10.4%$−2.39 to $−2.14
Nov '264 analysts▲ +4.2%$−0.43 to $−0.42▼ −212.0%$−0.13 to $−0.42▼ −91.3%$−0.22 to $−0.42
Feb '272 analysts29 of 30 days+3.4% so far29 of 90 days+3.4% so far▲ +3.4%$−0.54 to $−0.52

Contributors at both ends of the window: FY26 5 and 4. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from FY26 on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.

Consensus EBITDA · FY26
$0.5B
4 analysts · low $−0.5B, high $0.7B · thin coverage
Multiple · today's trailing P/E
6.1×
$15.48 (as of close, Nov 13, 2026) ÷ $2.54, the last four reported quarters, including EPS computed by Tenet
×
Receipt · NRIX · FY26Nov 13, 2026
Implied, a share
Waiting

We hold no net cash and no diluted share count for this company, so an EBITDA multiple cannot be bridged to a price a share here. The sum stops rather than guessing the bridge.

Drag the multipleWe hold no fiscal-year P/E record for this company, so the track carries only the multiples we can name.
5×6×8×10×12×
today 6.1×

Each point on the line is a multiple, and the flag is the price it implies for FY26. Past multiples are context, not a guide to future ones.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Growth over a negative base is not meaningful. Consensus EPS is a loss in FY26, so there is neither a multiple of those earnings to pay nor a rate to grow from.

How much do analysts disagree?

For FY30, estimates run from $−1.64 to $−0.78 around an average of $−1.16, drawn by 1 analyst.

FY26E4 analysts
$−6.17 to $6.11 · $12.28 wide
FY27E4 analysts
$−3.48 to $−0.64 · $2.84 wide
FY28E3 analysts
$−30.46 to $25.98 · $56.45 wide
FY29E1 analyst
$−2.41 to $−1.15 · $1.26 wide
FY30E1 analyst
$−1.64 to $−0.78 · $0.86 wide

The dashed line is FY25 filed $−3.05, on the GAAP basis.

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Nurix Therapeutics to lose $0.42 a share in the November quarter, the average of 4 estimates. Results are expected by Feb 1, 2027.

0
$−0.83
$−0.42high $−0.15
low $−0.71
Nov 2025 quarterfiled · GAAPNov 2026 quarterconsensus · Street basis · 4 analysts
Expected report
Feb 1, 2027
Expected by Feb 1. An estimate, not a date the company has set. Companies move it.
Revenue expected · November quarter
$38.0M
4 analysts, 7.5 to 59.9 in $M · 13.6 in the same quarter a year ago

A year ago this quarter was a loss, so the change from it is not a percentage and none is printed. For the February quarter, analysts expect a loss of $0.52 a share.

Does Nurix Therapeutics usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Nurix Therapeutics begins on Jul 6, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported. The next report is expected by Feb 1, 2027.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Our record, one quarter per report
Nov '23left out
Feb '24left out
May '24left out
Aug '24left out
Nov '24left out
Feb '25left out
May '25left out
Aug '25left out
Nov '25left out
Feb '26left out
May '26left out
Aug '26left out
reportsFeb 1
Nov '26
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Nurix Therapeutics on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow −85.4% in FY27. Consensus EPS is a loss in FY27, so there is no EPS growth rate to take apart.

4 analysts publish an EPS estimate for FY26 and 4 publish revenue. Coverage thins with distance: 1 EPS estimate for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
44
FY26E
44
FY27E
43
FY28E
21
FY29E
21
FY30E
The FY26 panel held 12 analysts when our record of it began on Jul 6, 2026 and holds 4 tonight.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
−0.00.40.7historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 4 revenue estimates for FY26, 2 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
−33.85−2.8128.24historyStreet forecastFY22FY25FY30E

Out-year bands widen as fewer analysts publish: 4 EPS estimates for FY26, 1 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed0.1—−3.05————as filed6.1×
FY26E0.70.7 to 0.7▲711.9%a2.35−6.17 to 6.11n/ca0.50.30.154 · 46.6×
FY27E0.10.0 to 0.2▼85.4%−2.14−3.48 to −0.64▼190.9%−0.2−0.20.094 · 4—
FY28E0.20.0 to 0.5▲145.1%−0.97−30.46 to 25.98—−0.1−0.10.124 · 3—
FY29E0.20.2 to 0.3n/cb−1.70−2.41 to −1.15n/cb−0.1−0.10.092 · 1—
FY30E0.30.2 to 0.4▲57.2%−1.16−1.64 to −0.78—−0.1−0.10.092 · 1—

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 4 EPS estimates for FY26. Not investment advice.

What do analysts expect Nurix Therapeutics to earn in FY26?

Analysts expect Nurix Therapeutics to earn $2.35 a share in FY26, the average of 4 estimates as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.